Options for those progressing on anti-PD1 - Early Clinical Trials and Reports

Here  - early agents in combinations, some promising for those progressing on anti-PD1 monotherapy!

Abstract 9514
Treatment after progression on monotherapy with anti PD1 (pembro)
Adding ipilimumab:
Complete Response rate (CR) 13%
Overal Response Rate (ORR) 45%

Abstract 9515
Tilsotolimod (TLR9 agonist) + IPI in patients progressing on anti-PD1 monotherapy
21 pts
Disease Control Rate -71%
Overall Response Rate 38.1%

Abstract 9513
SD-101 is a TLR9 agonist administered by local injection
By targeting TLR9, SD-101 helps dendritic cells to convert in APCs (Antigen Presentation Cells) and stimulates the anti-tumor activity of T-cells.

Trial SD-101 + Pembrolizumab
54 patients treated with SD-101 in an 8-mg dose in one lesion and 2-mg dose per lesion for two to four lesions beginning 21 days following the first dose pembrolizumab dose.

Efficacy
PFS 6 months -76%
ORR- 70% in naive patients (no previous treatment)
ORR -15 % in patients previously treated with an anti-PD1